CA2701118A1 - Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases - Google Patents
Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases Download PDFInfo
- Publication number
- CA2701118A1 CA2701118A1 CA2701118A CA2701118A CA2701118A1 CA 2701118 A1 CA2701118 A1 CA 2701118A1 CA 2701118 A CA2701118 A CA 2701118A CA 2701118 A CA2701118 A CA 2701118A CA 2701118 A1 CA2701118 A1 CA 2701118A1
- Authority
- CA
- Canada
- Prior art keywords
- domain
- day
- dose
- azli
- inhalable aerosol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000019693 Lung disease Diseases 0.000 title claims abstract description 36
- 230000036541 health Effects 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims description 173
- KPPBAEVZLDHCOK-JHBYREIPSA-N (2s,3s)-3-[[(2z)-2-(2-azaniumyl-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-2-methyl-4-oxoazetidine-1-sulfonate;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 KPPBAEVZLDHCOK-JHBYREIPSA-N 0.000 title claims description 99
- 229950010471 aztreonam lysine Drugs 0.000 title claims description 98
- 230000006735 deficit Effects 0.000 title description 2
- 239000000443 aerosol Substances 0.000 claims abstract description 394
- 208000024891 symptom Diseases 0.000 claims abstract description 174
- 239000003814 drug Substances 0.000 claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 261
- 239000011780 sodium chloride Substances 0.000 claims description 143
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 138
- 239000006199 nebulizer Substances 0.000 claims description 116
- 239000002245 particle Substances 0.000 claims description 100
- 229960003644 aztreonam Drugs 0.000 claims description 90
- 230000000241 respiratory effect Effects 0.000 claims description 89
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 88
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 claims description 87
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 73
- 238000000034 method Methods 0.000 claims description 68
- 239000000843 powder Substances 0.000 claims description 67
- 206010036790 Productive cough Diseases 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 47
- 208000024794 sputum Diseases 0.000 claims description 46
- 210000003802 sputum Anatomy 0.000 claims description 46
- 210000004072 lung Anatomy 0.000 claims description 41
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 claims description 25
- 230000007423 decrease Effects 0.000 claims description 24
- 230000008447 perception Effects 0.000 claims description 22
- 229960000707 tobramycin Drugs 0.000 claims description 21
- 230000002685 pulmonary effect Effects 0.000 claims description 19
- 230000002996 emotional effect Effects 0.000 claims description 14
- 229940041682 inhalant solution Drugs 0.000 claims description 12
- 230000029087 digestion Effects 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 239000004472 Lysine Substances 0.000 abstract description 8
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 abstract description 6
- 238000011866 long-term treatment Methods 0.000 abstract 1
- 229940068196 placebo Drugs 0.000 description 101
- 239000000902 placebo Substances 0.000 description 101
- 230000008859 change Effects 0.000 description 79
- 230000004044 response Effects 0.000 description 43
- 230000006872 improvement Effects 0.000 description 35
- 230000000694 effects Effects 0.000 description 29
- 239000003242 anti bacterial agent Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 23
- 229940088710 antibiotic agent Drugs 0.000 description 22
- 230000003247 decreasing effect Effects 0.000 description 22
- 238000002560 therapeutic procedure Methods 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- 238000012216 screening Methods 0.000 description 16
- 230000003115 biocidal effect Effects 0.000 description 15
- 201000010099 disease Diseases 0.000 description 15
- 208000015181 infectious disease Diseases 0.000 description 14
- 230000000244 anti-pseudomonal effect Effects 0.000 description 13
- 230000002411 adverse Effects 0.000 description 12
- 210000000038 chest Anatomy 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 230000009325 pulmonary function Effects 0.000 description 9
- 230000008901 benefit Effects 0.000 description 8
- 229960004099 azithromycin Drugs 0.000 description 7
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000005713 exacerbation Effects 0.000 description 7
- 230000004199 lung function Effects 0.000 description 7
- 229960003646 lysine Drugs 0.000 description 7
- 230000002238 attenuated effect Effects 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 108010067396 dornase alfa Proteins 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 229940124630 bronchodilator Drugs 0.000 description 5
- 229960000533 dornase alfa Drugs 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 238000011269 treatment regimen Methods 0.000 description 5
- HZRUTVAFDWTKGD-JEDNCBNOSA-N (2s)-2,6-diaminohexanoic acid;hydrate Chemical compound O.NCCCC[C@H](N)C(O)=O HZRUTVAFDWTKGD-JEDNCBNOSA-N 0.000 description 4
- 241000020730 Burkholderia cepacia complex Species 0.000 description 4
- 238000000729 Fisher's exact test Methods 0.000 description 4
- 208000032536 Pseudomonas Infections Diseases 0.000 description 4
- 238000012387 aerosolization Methods 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000003292 diminished effect Effects 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 210000000440 neutrophil Anatomy 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000013125 spirometry Methods 0.000 description 4
- 229940035289 tobi Drugs 0.000 description 4
- 230000001052 transient effect Effects 0.000 description 4
- 208000017667 Chronic Disease Diseases 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 206010052251 Respiratory tract congestion Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 230000008376 long-term health Effects 0.000 description 3
- 230000008518 non respiratory effect Effects 0.000 description 3
- 238000009613 pulmonary function test Methods 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 108010078777 Colistin Proteins 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 235000019766 L-Lysine Nutrition 0.000 description 2
- 206010023848 Laryngeal pain Diseases 0.000 description 2
- 238000000585 Mann–Whitney U test Methods 0.000 description 2
- 206010028735 Nasal congestion Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000122973 Stenotrophomonas maltophilia Species 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 229960003346 colistin Drugs 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 230000027950 fever generation Effects 0.000 description 2
- 229960000289 fluticasone propionate Drugs 0.000 description 2
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000002452 interceptive effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000006651 lactation Effects 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 229960002306 lysine monohydrate Drugs 0.000 description 2
- 238000009115 maintenance therapy Methods 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 2
- 229940124624 oral corticosteroid Drugs 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000000554 physical therapy Methods 0.000 description 2
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 2
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 229960002052 salbutamol Drugs 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000009469 supplementation Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 241001673062 Achromobacter xylosoxidans Species 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000861718 Chloris <Aves> Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010051301 Exercise tolerance decreased Diseases 0.000 description 1
- 229940126656 GS-4224 Drugs 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010021036 Hyponatraemia Diseases 0.000 description 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 101150034459 Parpbp gene Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010040742 Sinus congestion Diseases 0.000 description 1
- 206010041101 Small intestinal obstruction Diseases 0.000 description 1
- 206010043521 Throat irritation Diseases 0.000 description 1
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940112141 dry powder inhaler Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 239000003509 long acting drug Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940107568 pulmozyme Drugs 0.000 description 1
- 206010037833 rales Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 229960005018 salmeterol xinafoate Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US99707207P | 2007-10-01 | 2007-10-01 | |
| US99707107P | 2007-10-01 | 2007-10-01 | |
| US60/997,071 | 2007-10-01 | ||
| US60/997,072 | 2007-10-01 | ||
| PCT/US2008/076431 WO2009045706A1 (en) | 2007-10-01 | 2008-09-15 | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of life in lung diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2701118A1 true CA2701118A1 (en) | 2009-04-09 |
Family
ID=40032482
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2701118A Abandoned CA2701118A1 (en) | 2007-10-01 | 2008-09-15 | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7973029B2 (enExample) |
| EP (1) | EP2200608A1 (enExample) |
| JP (1) | JP2010540539A (enExample) |
| KR (1) | KR20100093037A (enExample) |
| CN (1) | CN101951906A (enExample) |
| AR (1) | AR068514A1 (enExample) |
| AU (1) | AU2008307268A1 (enExample) |
| BR (1) | BRPI0817636A2 (enExample) |
| CA (1) | CA2701118A1 (enExample) |
| EA (1) | EA201070336A1 (enExample) |
| IL (1) | IL204593A0 (enExample) |
| MX (1) | MX2010003618A (enExample) |
| NZ (1) | NZ584269A (enExample) |
| TW (1) | TW200927193A (enExample) |
| WO (1) | WO2009045706A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| DK2301524T3 (da) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner |
| CN104784159A (zh) * | 2015-04-15 | 2015-07-22 | 苏州惠仁生物科技有限公司 | 氨曲南粉雾剂的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5152456A (en) | 1989-12-12 | 1992-10-06 | Bespak, Plc | Dispensing apparatus having a perforate outlet member and a vibrating device |
| EP0615470B1 (en) | 1991-12-04 | 1995-12-13 | The Technology Partnership Public Limited Company | Fluid droplet production apparatus and method |
| DE19953317C1 (de) | 1999-11-05 | 2001-02-01 | Pari Gmbh | Inhalationsvernebler |
| US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
| US7214364B2 (en) | 2000-12-27 | 2007-05-08 | Corus Pharma, Inc. | Inhalable aztreonam lysinate formulation for treatment and prevention of pulmonary bacterial infections |
| US7138419B2 (en) * | 2000-12-27 | 2006-11-21 | Corus Pharma, Inc. | Process for manufacturing bulk solutions and a lyophilized pure α-aztreonam lysinate |
| DK2301524T3 (da) | 2000-12-27 | 2013-07-15 | Gilead Sciences Inc | Inhalerbar aztreonam uden arginin til behandling og forebyggelse af bakterielle lungeinfektioner |
| DE10102846B4 (de) | 2001-01-23 | 2012-04-12 | Pari Pharma Gmbh | Aerosolgenerator |
-
2008
- 2008-09-15 WO PCT/US2008/076431 patent/WO2009045706A1/en not_active Ceased
- 2008-09-15 KR KR1020107009839A patent/KR20100093037A/ko not_active Withdrawn
- 2008-09-15 NZ NZ584269A patent/NZ584269A/en not_active IP Right Cessation
- 2008-09-15 MX MX2010003618A patent/MX2010003618A/es not_active Application Discontinuation
- 2008-09-15 BR BRPI0817636A patent/BRPI0817636A2/pt not_active IP Right Cessation
- 2008-09-15 AU AU2008307268A patent/AU2008307268A1/en not_active Abandoned
- 2008-09-15 JP JP2010527021A patent/JP2010540539A/ja active Pending
- 2008-09-15 EP EP08836327A patent/EP2200608A1/en not_active Withdrawn
- 2008-09-15 CN CN2008801170106A patent/CN101951906A/zh active Pending
- 2008-09-15 US US12/210,965 patent/US7973029B2/en not_active Expired - Fee Related
- 2008-09-15 EA EA201070336A patent/EA201070336A1/ru unknown
- 2008-09-15 TW TW097135359A patent/TW200927193A/zh unknown
- 2008-09-15 CA CA2701118A patent/CA2701118A1/en not_active Abandoned
- 2008-09-15 AR ARP080104006A patent/AR068514A1/es not_active Application Discontinuation
-
2010
- 2010-03-18 IL IL204593A patent/IL204593A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0817636A2 (pt) | 2019-09-24 |
| IL204593A0 (en) | 2010-11-30 |
| MX2010003618A (es) | 2010-04-21 |
| US7973029B2 (en) | 2011-07-05 |
| AR068514A1 (es) | 2009-11-18 |
| CN101951906A (zh) | 2011-01-19 |
| TW200927193A (en) | 2009-07-01 |
| NZ584269A (en) | 2012-06-29 |
| JP2010540539A (ja) | 2010-12-24 |
| EP2200608A1 (en) | 2010-06-30 |
| EA201070336A1 (ru) | 2011-06-30 |
| KR20100093037A (ko) | 2010-08-24 |
| US20090124594A1 (en) | 2009-05-14 |
| WO2009045706A1 (en) | 2009-04-09 |
| AU2008307268A1 (en) | 2009-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8664187B2 (en) | Methods of treatment of endobronchial infections | |
| Retsch-Bogart et al. | Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis | |
| EP0734249B1 (en) | Novel and improved aminoglycoside formulation for aerosolization | |
| Retsch‐Bogart et al. | A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection | |
| Campbell et al. | Use of aerosolized antibiotics in patients with cystic fibrosis | |
| AU2002231244B2 (en) | Inhalable aztreonam for treatment and prevention of pulmonary bacterial infections | |
| Schwarz et al. | Tobramycin safety and efficacy review article | |
| US7973029B2 (en) | Inhaled aztreonam lysine for the treatment of deficits in health-related quality-of-life in lung diseases | |
| US20260034154A1 (en) | Methods for treating newly diagnosed mycobacterium avium complex lung infections | |
| Geller et al. | Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis | |
| JP2010540539A5 (enExample) | ||
| US20240342239A1 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| US12178841B2 (en) | Treatment of non-cystic fibrosis bronchiectasis | |
| EA052469B1 (ru) | Лечение некистозных фиброзных (немуковисцидозных) бронхоэктазов | |
| Renee Crowther Labiris et al. | Dry Powder versus Intravenous and Nebulized Gentamicin in Cystic Fibrosis and Bronchiectasis: A Pilot Study | |
| Hoffman et al. | Inhaled Aztreonam Lysine for Cystic Fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20140916 |